<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70999">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02181504</url>
  </required_header>
  <id_info>
    <org_study_id>150998-002</org_study_id>
    <secondary_id>BAMBOO</secondary_id>
    <nct_id>NCT02181504</nct_id>
  </id_info>
  <brief_title>A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a safety and efficacy study of abicipar pegol in patients with neovascular
      age-related macular degeneration to establish comparability between Japanese and
      non-Japanese.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye</measure>
    <time_frame>Baseline, Week 16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in BCVA in the Study Eye</measure>
    <time_frame>Baseline, Week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients with a BCVA Gain of ≥15 Letters in the Study Eye on the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale</measure>
    <time_frame>Baseline, 20 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients with a BCVA Gain of ≥10 Letters in the Study Eye on the ETDRS Scale</measure>
    <time_frame>Baseline, 20 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Central Retinal Thickness (CRT) in the Study Eye</measure>
    <time_frame>Baseline, Week 16, Week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Levels of Abicipar</measure>
    <time_frame>20 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>abicipar pegol 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abicipar pegol 1 mg administered to the study eye by intravitreal injection at day 1, weeks 4 and 8, followed by a sham procedure at weeks 12 and 16.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>abicipar pegol 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abicipar pegol 2 mg administered to the study eye by intravitreal injection at day 1, weeks 4 and 8, followed by a sham procedure at weeks 12 and 16.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ranibizumab 0.5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>abicipar pegol</intervention_name>
    <description>Abicipar pegol administered to the study eye by intravitreal injection at day 1, weeks 4 and 8.</description>
    <arm_group_label>abicipar pegol 1 mg</arm_group_label>
    <arm_group_label>abicipar pegol 2 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranibizumab</intervention_name>
    <description>Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.</description>
    <arm_group_label>ranibizumab 0.5 mg</arm_group_label>
    <other_name>Lucentis®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sham procedure</intervention_name>
    <description>Sham procedure to the study eye at weeks 12 and 16.</description>
    <arm_group_label>abicipar pegol 1 mg</arm_group_label>
    <arm_group_label>abicipar pegol 2 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ethnically Japanese

          -  Diagnosis of wet age-related macular degeneration in at least 1 eye

          -  Best corrected visual acuity of 20/32 to 20/320 in the study eye and 20/200 or better
             in the fellow eye

        Exclusion Criteria:

          -  Hypersensitivity, allergy, or anaphylactic reaction to iodine or shellfish

          -  Cataract or refractive surgery within the last 3 months

          -  History of vitrectomy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nihon University Hospital</name>
      <address>
        <city>Chiyoda-ku,Tokyo</city>
        <zip>101-8309</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1 Fukushima Medical University</name>
      <address>
        <city>Fukushima-shi</city>
        <zip>960-1295</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyushu University Hospital</name>
      <address>
        <city>Kita-ku, Fukuoka-shi Fukuoka</city>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital</name>
      <address>
        <city>Kita-ku, Okayama-shi Okayama</city>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shiga University</name>
      <address>
        <city>Otsu-shi</city>
        <zip>520-2192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Women's Medical University</name>
      <address>
        <city>Shinjuku-ku</city>
        <zip>162-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagoya University Hospital</name>
      <address>
        <city>Showa-ku, Nagoya-shi Aichi</city>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Takeuchi Eye Clinic</name>
      <address>
        <city>Taito Ku Tokyo</city>
        <zip>111-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Musashi Dream Clinic</name>
      <address>
        <city>Tennoji-ku Osaka</city>
        <zip>543-0027</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juntendo University Urayas</name>
      <address>
        <city>Urayasu-shi</city>
        <zip>279-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otakeganka Tsukimino Clinic</name>
      <address>
        <city>Yamato Kanagawa</city>
        <zip>242-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.allerganclinicaltrials.com</url>
    <description>More information</description>
  </link>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>December 18, 2015</lastchanged_date>
  <firstreceived_date>July 2, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
